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Increasing numbers of poorly water soluble drugs in development has intensified need for bio-enabling 
formulations including Lipid-Based Formulations (LBF) and Solid Dispersions (SD). Resultantly, a data-driven 
approach is required to increase formulation development efficiency. This review provides a retrospective 
analysis of molecular and biopharmaceutical properties of drugs commercialised as LBFs or SDs. A 
comprehensive stepwise statistical analysis of LBF and SD drug properties was conducted and compared to 
drugs not commercialised via either technology (Others), aiming to identify key predictors of successful 
formulation development. This review demonstrates LBF and SD drugs differ significantly in molecular weight, 
polar surface area, rotatable bonds and hydrogen bond acceptor count. Meanwhile, LBF and SD drugs display 
significantly different aqueous solubility, lipophilicity, size, molecular flexibility, hydrogen bonding capacity and 
rule-of-5 violations versus Others. LBF and SDs were 3 and 5 times more likely to display >1 rule-of-5 violation 
versus Others, over 55% of LBF drugs exceeded the reported melting point guide of <150°C, while 24% of SD 
drugs contained >10 Hydrogen Bond Acceptors. Overall, by focusing on successfully commercialised drugs, this 
review provides improved understanding of links between drug properties and successful SD/LBF approaches, 
providing a framework for guiding pharmaceutical development on formulation approaches. 
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1. Introduction  
Increasing utility of and investment into bio-enabling formulations such as Lipid-Based Formulations (LBF) and 
Solid Dispersions (SD) has been fuelled through increasing prevalence of poorly water soluble drugs (PWSD) in 
development pipelines and the ensuing necessity for more non-traditional systems to successfully deliver 
them. Approximately 75-90% of all compounds in modern drug discovery programmes display solubility-
limited absorption, consequentially presenting the pharmaceutical industry with a “poor solubility challenge” 1-
4. Such modern drug candidates display high lipophilicity, poor aqueous solubility and resultant reduced oral 
bioavailability 5, 6. Such properties are common negative penalties traded for high potency and selectivity for 
contemporary lipophilic binding pockets or drug targets 7, 8. Recent drug discovery trends indicate a greater 
number of drugs emerging in the beyond “rule-of-5” (Ro5) chemical space 9, 10. This increasingly molecularly 
diverse pipeline portfolio creates need for bio-enabling approaches to achieve sufficient oral absorption in vivo 
10. Undoubtedly, an emerging burden in the pharmaceutical industry involves adjusting long standing traditions 
of drug delivery to develop new strategies and tools able to translate such non-optimal drugs into viable 
commercial products.  
PWSD encompass Class II/IV of the “Biopharmaceutics Classification System” (BCS) (Figure 1). The BCS aims to 
identify the rate limiting step to oral bioavailability as being either solubility or permeability. While the BCS is 
widely used to guide drug candidate and formulation development, it primarily serves a regulatory purpose 
and is rightly conservative in its estimates of in vivo solubility while also providing limited mechanistic 
assessment of in vivo permeability limitations. As a result, the BCS has been refined on several occasions to 
provide increased utility in guiding formulation development. The “Biopharmaceutics Drug Disposition 
Classification System” (BDDCS) aims to predict the drug disposition characteristics of novel drugs earlier in 
drug development by assessing drug metabolism rather than human intestinal permeability as a predictor of 
absorption, while also incorporating effects of metabolising enzymes and transporters in vivo and drug 
disposition in development 11, 12. It has been demonstrated to be applicable to both the Ro5 and beyond-Ro5 
chemical space 9. The “Developability Classification System” (DCS) aims to address the use of the sub-optimal 
aqueous solubility measurement implemented by the BCS/BDDCS 13 by providing an estimate of in vivo 
solubility using biorelevant media (i.e. Fasted Stated Simulated Intestinal Fluid). The DCS also considers the 
concept of a solubility limited absorbable dose (SLAD), which is the maximal dose that could potentially be 
absorbed, factoring in both biorelevant solubility in physiologically relevant fluid volumes in the 
gastrointestinal tract (GIT) and the compensatory effects of permeability on dissolution in vivo. The numerous 
classification systems developed have focused on identifying difficult-to-formulate compounds, and those 
likely to be amenable to formulation as bio-enabled preparations, however the choice of a specific formulation 
approach remains challenging. 
Bio-enabling formulations are drug delivery technologies specifically intended to improve the release, 
dissolution and absorption of PWSD 14. Through enhanced drug dissolution and absorption, bio-enabling 
formulations possess ability to provide necessary in vivo drug exposure not possible through more 
conventional dosage forms 15. Examples include lipid-based formulations (LBF), solid dispersions (SD), 
mesoporous silica formulations, salt formation, nanosized or micronized formulations and surfactant or 
cyclodextrin enabled formulations 7.  At present cumbersome, iterative formulation screening assays are often 
used to determine which bio-enabling formulation is most appropriate, and significant efforts are being made 
to refine this process by improving the efficiency of current bio-predictive screening tools and by moving 
towards data-driven drug and formulation development 16, 17. Contributory factors in guiding formulation 
choice can include in-house company expertise, equipment availability and cost. For these reasons the 
physiochemical properties of such drugs, and their biopharmaceutical implications, may be overlooked. 
However, a renewed emphasis is being placed on understanding the molecular properties of these drugs and 
their impact on biopharmaceutical properties, moving from simple classification systems to truly 
computationally informed pharmaceutics.  
Efforts have been made to advance computational pharmaceutics from predictions of intrinsic solubility, 
solubility in simulated intestinal fluids and permeability, to models predicting aspects of formulation 
developability related to either solubility or stability in LBFs and SDs from molecular structure 18-22. In addition 
to modelling efforts, decision trees allowing for differentiation between “conventional” and “enabled” 
technologies 23 as well as structured development approaches for LBFs and SDs have been suggested 24, 25. 
Despite such advances in the tailoring of formulation choice based on drug properties, analysis of the current 
landscape of commercial drugs utilising bio-enabling technologies in order to establish trends in 
physiochemical characteristics and molecular properties is lacking. The current review aims to provide a 
retrospective, top-down, analysis of the current landscape of commercial products, to identify which drug 
properties are likely to identify successful delivery technologies at an earlier stage in development. This review 
focuses on the commercial utility of the two most commonly encountered bio-enabling formulation 
approaches; Lipid-Based Formulations (LBF) and Solid Dispersions (SD), due to the extensive reports in the 
literature on their capacity to enhance oral delivery, and numerous examples of commercial successes as 
licensed drug products in clinical use.  
The current review aims to provide an up-to-date and comprehensive list of commercially available LBF and SD 
formulations, discuss trends in the type of drugs and formulations currently reaching the marketplace and 
identify key physicochemical and biopharmaceutical predictors of successful formulation development. In 
order to achieve these aims, the commercial examples to date of drug products formulated as either SDs or 
LBFs is examined and classified according to BDDCS class of the formulated active substance, while selected 
physiochemical characteristics and molecular properties of these commercial drugs are statistically analysed 
and compared to a list of compounds not produced via either technology. The aim of this analysis is to explore 
which drug properties signal suitability of a drug for LBFs or SDs, or moreover, properties which potentially 
distinguish between them. This analysis attempts to bridge a gap in current drug development, involving 
widespread use of drug likeness filters and ADME optimisation to guide drug discovery and refine drug 
candidate selection. While many merits exist for their use, there also exists a risk that current filters may be 
overly conservative and conceptually simplistic. As increasing numbers of drugs emerge beyond the preferred 
chemical space it could be argued that complementary use of “formulation likeness filters” in such instances 
could inform developers of bio-enabling technologies which may be appropriate, based on properties of their 
drug candidate, simultaneously analysing potential for success in terms of both drug likeness and bio-enabling 
potential. As the numbers of drug compounds using both LBF and SD in licensed commercial products 
continues to grow, so too does the database of information regarding suitable drugs compatible for such 
systems. This data bank could guide future commercial success of LBF and SD products, reflecting backwards in 






















2. Lipid-Based Formulations and Solid Dispersions as Bio-Enabling 
Formulations 
In response to this need to deliver challenging drug candidates orally, methods overcoming poor solubility are 
vital in drug development (26). Two such approaches methods involve the utilisation of LBF and SD. 
2.1 Lipid-Based Formulations 
The term “lipid-based formulation” spans a wide range of formulations composed of pure oils or mixtures of 
oils, surfactants and/or co solvents in various proportions as classified in the lipid formulation classification 
system (LFCS) 27, 28. Previous research has suggested that many of the marketed LBF products consist of Type II 
or III formulations, often referred to as self-emulsifying drug delivery systems (SEDDS) 29. These can 
spontaneously emulsify upon dispersion due to the presence of surfactants and hydrophilic excipients, 
decreasing reliance on endogenous lipid digestion to facilitate emulsification 7. LBFs have been traditionally 
employed for drug which display poor aqueous solubility and high lipophilicity (logP). The administration of 
lipid excipients enhances the drug solubilisation capacity of the GI environment, stimulating endogenous bile 
acid secretion, leading to production of a mixture of solubilising colloidal structures composed of endogenous 
and exogenous lipids 30. These can effectively solubilise the PWSD 26, 31, 32 and the drug is retained either 
solubilised or in a transiently supersaturated state allowing for increased absorption 26.  The “spring and 
parachute” analogy applies here to the generation and prolongation of supersaturation where the “spring” 
involves the self-emulsifying properties of the LBF, incorporating the solubilised active substance 33, while 
“parachute” refers to formulation additives which increase stability, reducing drug precipitation in vivo 34 
(Figure 2).   
LBFs are also biopharmaceutically advantageous regarding impact on intestinal permeability  35, metabolism 36 
and lymphatic transport 37, 38. Additionally, from a pharmaceutical manufacture standpoint, once acceptable 
manufacturing equipment is in place, large scale manufacture of LBFs is relatively low risk and less 
technologically demanding which can usually be completed on a smaller scale than other delivery technologies 
15, 39. 
2.2 Solid Dispersions 
The merits of SD to improve oral absorption has been demonstrated as far back as the 1960s. SDs are generally 
two-component systems, containing one or more active substances dispersed in an inert matrix. Depending on 
the physical state of the carrier, SDs are classified as either crystalline or amorphous, while the API can be also 
be presented as amorphous or crystalline particles or as a molecular dispersion 40. SDs can facilitate increased 
solubility and dissolution through a reduction in API particle size, potentially to a molecular level, enhanced 
wettability and porosity, and altered drug crystalline state, preferably to an amorphous state 41. In its most 
commonly used form, a SD involves dispersion of drug in an amorphous polymer matrix with drug present in 
the molecularly dispersed state (a glass solution) 42. This composition exploits the fact that the solubility of the 
dispersed or amorphous state can be much higher than comparative solubility of the most stable crystalline 
polymorph, thus, a supersaturated solution is more easily attained 7. Upon amorphisation, the impact of 
crystalline long range order on drug solubility and dissolution is largely reduced as intermolecular interactions 
are weaker and Gibbs free energy is increased 43, 44. Thus, SDs are considered useful for drugs which exhibit 
solid state limited solubility (i.e. ‘brick dust’ molecules), but can also be of merit for “grease ball” type 
molecules due to reduced particle size and increased hydrophilicity due to excipients 45, 46. SD systems contain 
stored potential energy similar to a “spring” which when dispersed can release and forms a supersaturated 
state when exposed to the GIT (Figure 2). The innate thermodynamic instability of the supersaturated state 
may lead to precipitation or in the case of amorphous SD premature recrystallization. A variety of excipients 
such as polymers can be utilised to act as a “parachute” in the prevention of precipitation or recrystallization 
and maintain the solubility advantage. Successive generations of SDs have been produced each providing 
updated and altered excipients such as polymers to maintain this amorphous solubility advantage or more 




















3.1 Dataset Selection 
An original databank of approximately 1000 drug compounds was collated from previous literature sources 9, 49 
using the BDDCS classification and an in house database of oral drug compounds commercially approved by 
the EMA and FDA between 2010 and 2017 50. Where information regarding BDDCS classification was not 
available, a drug’s BCS classification was used as a surrogate due to the same parameter of solubility being 
used in both classifications. This master databank was split into three, namely, drugs commercially developed 
as LBF, SD and Others i.e. not commercially developed via either technology. LBF and SD drugs were identified 
from previous literature referencing commercial products 7, 43, 51-58, along with analysis of the online databases 
of the US and EU respective drug licensing authorities (Food and Drug Administration, European Medicines 
Agency, Health Products Regulatory Authority of Ireland) where dosage, licencing and excipient information 
regarding all products was also then obtained. Where a product was identified in peer reviewed literature but 
was not authorised in these three areas another national authority was investigated to establish if the product 
had been commercialised. A LBF was defined as Class I-IV of the Lipid Formulation Classification System 59. All 
types of solid dispersions were considered based on description in product or published literature that the 
product is a SD (i.e. both amorphous versus crystalline API dispersed in amorphous carriers.) Omega-3-acid 
ethyl esters, Florfenicol and Silibinin were removed from the database due to the lack of drug property data 
available. Exclusion criteria for the Others list included any drugs used in LBF or SD commercial products, 
active metabolites and non-orally delivered drugs. The final datasets contained 49 drugs grouped as LBF, 37 as 
SD and 763 as Others drugs. When including only poorly soluble BDDCS Class II/IV drugs there remained 38 
drugs grouped as LBF, 30 as SD and 307 as Others drugs. 
3.2 Compilation of Physicochemical Descriptors 
Physiochemical properties to be assessed were identified and compiled from the literature publication BDDCS 
Applied to Over 900 Drugs 49. Physiochemical and molecular properties for the drugs not listed in Benet et al. 
were obtained from PubChem, DrugBank or ADMET Predictor 9.5 (Simulations Plus, USA). The final properties 
of the drugs analysed included: Molecular Weight (MW), Maximum Dosage Strength (MDS), Hydrogen Bond 
Acceptors (HBA), Hydrogen Bond Donors (HBD), Polar Surface Area (PSA), Measured Partition Coefficient 
(logP), Calculated Partition Coefficient (clogP), Percentage Excreted Unchanged in Urine (U%), pDose, 
Logarithm of Aqueous Solubility (logS), Partition Coefficient at pH 7.4 (logD7.4) , Rule-of-5 Violations (Ro5), pKa 
(Strongest Acidic), Melting Point (Tm) and Rotatable Bonds (RB). These are defined in Table 1.  
 
3.3 Statistical Analysis 
A stepwise statistical analysis approach was adopted using SPSS (IBM Corporation, US). Frequency 
distributions of the variables were graphed for each of the three groups and normality was checked visually 
with Q-Q and P-P plots. Ratios of samples sizes between the 3 groups were obtained. Variances of the datasets 
were analysed and compared to Levene’s Test for Equality of Variances. A p-value <0.05 indicated a violation 
of equal variance. The null hypotheses were that no differences were seen in a drug property between drug 
groups. Three separate comparison were made i.e. LBF vs SD; LBF vs Others; SD vs Others rather than a three-
group comparison, using for example ANOVA. This enabled use of the most appropriate comparison method 
based on assessment of data normality and equality of variance in each group and is in line with the null 
hypotheses identified. Comparison between groups were made using the t-test, Welch’s test, Bootstrap 
independent samples test (5000 samples) or Chi-Square test, all 2-sided, where appropriate. Rule-of-5 
violations was recoded to a category variable or ≤1 or >1 violation and Chi-Square tests were used to test 
independence of this categorical variable. If 1 or more cells had an expected count below 5, Fisher’s exact test 
was employed. A p-value of 0.05 was used as the significance level for all tests. Finally, in order to analyse only 
PWSD, subsets of the three datasets were created containing only BDDCS Class II/IV drugs and the statistical 





























4.1 Commercial Success to Date 
While previous studies have evaluated trends by comparing drugs formulations reported in scientific literature, 
this does not provide a true measure of clinical development success. Therefore, we envisage a gap in the 
literature in terms of a comprehensive list of drugs which have been commercially developed as either LBF or 
SD. Information involving product names, drug compounds and excipients used, dosage forms, strengths and 
the geographical areas in which the products were licensed was collated (Supplementary Materials). Some 
products have been subsequently withdrawn from the commercial market however, all products were licensed 
at one point in time.  
4.1.1 Commercial Lipid-Based Formulations 
LBF products have been successfully authorised internationally since the 1940s. Early examples of commercial 
products consisted of Type I formulations of the LFCS e.g. Drisdol® 60. As years progressed interest in self-
emulsifying systems intensified 26 and resulted in a large surge in increasingly complex Type III and IV LBF 
products in the 1980s-1990s 53. Review of the published literature and online databases of drug product 
regulatory authorities in the US and EU identified 67 commercial LBF products. As illustrated in Figure 3, a 
higher number of the LBF products have been authorised in the US (47/67) compared to the EU (26/67). 
Differences in the number of marketed products could represent strategic commercial decisions based on 
factors such as level of clinical demand or regulatory burden.   
In a small number of cases more than one dosage form e.g. capsule and oral solution, have been produced for 
the same drug product (6/67 products). In comparison, multiple dosage strengths have been licensed almost 
half of the products (28/67 products). It was observed that soft gelatin capsules dominantly account for the 
most popular LBF product dosage form (40/67), followed by oral solutions (10/67), hard capsules (10/67) and 
oral suspensions (1/67) (Figure 4). There are also 6 products which are controlled release, demonstrating a 
further drug delivery advantages of LBFs. These are extended release capsules (3/67), extended release 
suspension (1/67) prolonged release capsule (1/67) and sustained release granules (1/67). Clearly, soft gelatin 
capsules represent the more prevalent dosage form as they can safely encapsulate liquid dosage forms in 
comparison to hard capsules. While there has been successful suspensions produced 61, solutions remain the 
most popular approach for commercial products according to our analysis. 
In terms of year of authorisation, it can be seen (Figure 5) that the period of 2000-2009 contained the highest 
number of commercial LBF approvals (37%). As such, combining the 1990s and 2000s accounts for 63% of all 
commercial LBF products. However, this spike in approvals did not continue into the period since 2010 where 
only 9% of all LBF products have been commercialised. Overall, the findings here are comparable to analysis 
examining growth in the number of LBF/SEDDS publications in PubMed from 1966 to 2016 where they saw a 
large surge of publication numbers from the mid-1990s 26. Finally, a number of the listed products have been 
either discontinued or withdrawn from the market (12/67). No trends were evident where the reasons for 
withdrawal were linked to reasons of efficacy, safety nor stability. In the majority of cases a lack of clinical 
demand or switch to another dosage form was cited by the manufacturer.  
4.1.2 Commercial Solid Dispersions 
The earliest example of a commercial SD product is Cesamet® (Nabilone) from 1982 62. Overall 39 commercial 
SD products were identified. Four of these have been marketed under a different brand name in a different 
region (Certican® = Zortress®, Incivek® = Incivo®, Cokiera® = Viekira XR®, Galvumet® = Eucreas®). Compared to 
LBFs, commercial SDs form a smaller number of licensed products, which may reflect that LBF products were a 
more established commercial pathway in the 1980’s and 1990’s, relative to SDs 26, 63. As an example, the first 
LBF was approved over 40 years before the first SD commercial products (Drisdol®, 1941 and Cesamet®, 1982). 
When commercial SD products manufacturing methods were analysed we found the majority of products were 
produced via either spray drying or melt extrusion methods in line with previous research analysis 45.  
The widespread global market for SD products is apparent. From Figure 3 close to 50% of SD commercial 
products are authorised in both the United States and EU markets. Multiple dosage strengths were seen for a 
majority of products (23/39), similar to LBFs, potentially due to scalability and manufacture of dose 
proportional preparations of SDs. In terms of dosage forms immediate release tablets are most popular 
(27/39) (Figure 4). While capsules (4/39) and granules for oral suspension (1/39) are also seen, as well as 
controlled release tablets and capsules, in the form of extended, delayed or prolonged release. 5/39 identified 
SD products have been either discontinued or withdrawn from the market. Upon review no evidence could be 
found to suggest the majority of removals were due to efficacy or safety issues and were voluntary due to 
declining clinical demand or alternative dosage forms. Conversely, in the case of Rezulin® (Trogslitazone), its 
removal was linked to the development severe idiosyncratic hepatocellular injury 64. However, this is due to 
the drugs intrinsic toxicity rather than lack of effective formulation delivery. 
In contrast to only 9% of LBF products, 54% of SD commercial products have been authorised since 2010 
(Figure 5), demonstrating a sharp growing development trend toward SDs in recent years. It has previously 
been suggested that SD formulation technologies have been embraced to a much greater extent since 2012 45, 
with comparative spikes in terms of related research articles seen from 2010-2015 54. As evidence of the 
commercial success of SD technology, Harvoni® (Gilead Sciences, Inc.), containing Ledipasvir and Sofosbuvir, 
used to treat chronic Hepatitis C was second in the blockbuster list of drugs ranked by sales revenue in 2015 65. 
 
4.1.3 Commercial Products via Both Formulation Technologies 
Four drugs have been commercially produced via both LBF and SD technologies. These are Fenofibrate, 
Lopinavir, Ritonavir and Nimodipine. In the case of Lopinavir, it was originally produced in combination with 
Ritonavir in Kaletra® as an LBF capsule and subsequently replaced by AbbVie Inc.©  with the SD tablet form 
exhibiting a higher dose loading capacity. This resulted in a reduced pill burden and aided compliance while 
also providing the added advantage of absence of food effect 66. Similarly, Ritonavir has also been 
commercialised as both a SD and LBF in Norvir® 67. In this case, original liquid filled capsules containing 
Ritonavir in an ethanol, surfactant and water based solution were withdrawn from the market due to 
discovery of a previously unknown polymorph, leading to a significant decline in drug solubility and potential 
for poor bioavailability 68, 69. When this original form was removed from the market, patients were encouraged 
to switch to the oral liquid form. In 1999, AbbVie Inc. (previously Abbott), applied for approval of an LBF soft 
gelatine capsule form overcoming this stability problem which required refrigeration. Ultimately in 2010, this 
LBF form was replaced by an SD 100 mg tablet which overcame the requirement for refrigeration, which 
improves convenience. Therefore, in two cases, choices of both LBF and SDs were largely based on commercial 
strategies (Fenofibrate and Nimodipine), whereas for Lopinavir and Ritonavir, initially the more established 
formulation strategy of LBFs were launched, however, due to problems with dose loading and stability were 
ultimately replaced with SDs. Overall, this relatively small overlap of drugs produced by both technologies 
observed, could suggest existence of distinctive drug properties which render a drug candidate more suitable 
for SD delivery over LBF delivery or vice versa.  
 
4.2 BDDCS Classifications 
The three drug sets were grouped according to BDDCS classification. These visual representations are found in 
Figure 6. As expected, the highest numbers of LBF (76%) and SD (60%) drugs in commercial products belong to 
BDDCS Class II. Also as anticipated, the second highest proportion of SD commercially used drugs come from 
BDDCS Class IV. In contrast, the second highest proportion of LBF drugs were found to be BDDCS Class I which 
indicates that, not only solubility limited compounds are successfully commercialised via LBFs. This most likely 
reflects a strategic commercial decision, as opposed to a strategy to address  a solubility or permeability 
limitation, and may reflect that the large scale manufacture of LBFs are generally well established, and require 
relatively lower technologically input compared to other more expensive bio-enabling platforms such as SDs 15.  
 
4.3 Retrospective Statistical Analysis of Properties of Commercialised LBF and SD Drug 
Compounds.  
Molecular properties of drugs previously commercialised using LBF and SD formulation technologies were 
statistically compared with properties of drug substances not commercialised via either technology. Tabular 
results of the statistical analysis are shown in Supplementary Materials. A visual representation of significant 
differences obtained is illustrated in Figure 7. 
Upon analysis of all BDDCS classes, 8/15 properties were significantly different between the LBF and Others 
datasets, namely MW, logP, %U, logS, logD7.4, Ro5, Tm and clogP. In addition to these 8 properties HBA, RB and 
PSA were also found to be significantly different between the SD versus Others datasets. Therefore, these 
properties can be predictive of suitability for commercial success via LBF or SD technologies according to the 
current commercial climate of both sets of drugs. While no clear trends for the properties of pKa (strongest 
acidic), MDS and pDose were differentiated between groups, thus, these properties did not appear useful in 
predicting suitability nor indicative of unsuitability for either formulation type. Between LBF and SD datasets 
significant differences in drug properties were observed as SDs displayed significantly higher mean HBA, RB, 
MW and PSA, compared to LBFs.  
Subsequently, a subset analysis was performed on BDDCS Class II/IV drugs (low solubility) to explore whether 
results would be altered by excluding high solubility drugs, typically delivered using conventional methods. 
This subset decreased the numbers in the LBF group by 22% (n = 38), the SD group by 19% (n = 30) and the 
Others group by 60% (n = 307). In terms of comparisons between LBF versus Others within this low solubility 
datasets, this resulted in the parameters of Ro5 (p = 0.086), MW (p = 0.129) and Tm (p = 0.051) being no longer 
significant, albeit marginally in the case of Tm. Conversely, differences in both MDS ( ** p = 0.006) and pDose ( 
*p = 0.026) between LBF and Others gained significance in the low solubility dataset. In terms of comparisons 
between SD and Others, the low solubility subset did not result in loss of significance to any observation, while 
MDS ( ** p = 0.003), pDose ( * p = 0.037) and HBD ( * p = 0.03) also gained significance. The low solubility 



















Based on the statistical analysis of formulation types by drug properties the following general trends have 
been observed.  
5.1 Molecular Weight (MW) 
Drugs commercialised as both LBF and SD pharmaceutical products displayed significantly larger MW 
compared to those commercialised via traditional formulation approaches (i.e. Others). Comparatively, SDs 
displayed significantly greater mean MWs (586.6g/mol) versus LBFs (448.2g/mol) suggesting that while both 
LBFs and SDs express potential to accommodate high MW drugs, SD approach may offer greater opportunities 
at the higher MW range. Additionally, only LBF, not SD drugs, lost significance versus Others when a low 
solubility dataset was analysed, suggesting that as MW increases any benefits LBF confer for PWSDs are not as 
prevalent and preference for SD platforms prevails.  
These results reflect drug development trends over recent decades of increasing MW of drug molecules in 
drug development pipelines 70-72. In the two last decades, there has been consistent trends for higher MW 
drugs being brought to market, exemplified when in 2016 and 2017 for the first time, average MW for new 
FDA approved oral drugs exceeded 500g/mol 73, with widespread increases in MW observed not merely due to 
approval of a small proportion of very high MW drugs. Such trends fall outside both the Lipinski Ro5 and the 
“rule of three” for fragment based drug discovery 74. Resultantly, this sharp increase has prompted questioning 
regarding the justification of MW as a property of “drug-likeness” 73.  
The trend for high MW observed here should be considered in line with the earlier reported trend for 
increasing use of SD approaches in the last decade. It is unclear whether these reflect independent trends in 
technological advances of both SD and increasing drug candidate MW or complementarity of both. However, it 
is clear that SDs offer a more commercially successful track record for high MW drugs. As most recently 
evidenced by the high MW antiviral, enzyme inhibitor drugs being delivered commercially in this manner e.g. 
Cokiera®, Epclusa®, Zelboraf®. These results are broadly supportive of the general rule of thumb that 
molecules with a MW of >300 g/mol can more easily be transformed into an amorphous state 75. Here, we 
uncovered only 2/37 drugs commercialised as SDs with MW <300 g/mol. It has also been suggested that 
comparatively high MW increases glass forming ability (GFA) of a drug 75, 76. While a higher solubility advantage 
was also demonstrated for higher MW drugs as a result of in silico predictive modelling of the amorphous 
solubility advantage 77. Resultantly, from our analysis MW provides a distinguishing property for potential 
commercial success between LBFs and SDs at the higher end of the MW scale.  
 
5.2 Melting Point (Tm) 
A significantly smaller mean Tm was found for LBF drugs (160.81°C) vs Others (181.18°C). This significance was 
lost, albeit marginally, when a low solubility dataset was analysed. When the variances of Tm among groups 
was analysed, the smallest spread of values was found amongst the SD group. While the lowest Tm values for 
LBF and Others groups respectively were 38°C and 43°C, the lowest Tm of a drug produced as a SD was 
approximately double these figures (80.5°C). Tm is often cited as an important drug characteristic influencing 
solubility in lipid vehicles, as an indicator of the energy required to break intermolecular bonds and overcome 
the crystal lattice energy. Drugs possessing a high crystal lattice energy along with a moderate logP value (>2) 
are termed “brick dust” 61, typically possessing poor solubility in lipids due to limited capacity to dissociate 
from the solid form and are not ideal candidates for LBFs 7, 26. Previous work has demonstrated, that addition 
of Tm improved computational predictions of drug solubility in triglyceride vehicles 21. It has been reported that 
in order for reasonable solubility in lipid vehicles, a low to intermediate Tm was preferable, and a Tm <1500C 
was proposed as a baseline for the selection of LBFs as potential enabling formulation approaches 77-80. 
However, in this analysis more than half (i.e. 55%) of commercially licensed LBFs exceeded this commonly 
recommended value of 150°C. A subset analysis revealed however, that the mean maximum dosage strength 
was significantly lower for drugs exceeding this value (i.e. 148.62mg for drugs <150°C compared to 81.48mg 
for >150°C).  Overall, this would suggest that while low to intermediate Tm may be still be recommended, 
particularly for higher dose products,  in the case of low dose/highly potent drugs, a Tm in excess of 150°C may 
not be limiting.  
Tm was not observed to be a predictor of SD commercial success. This was unexpected as Tm was previously 
demonstrated to be an important predictor for the solubility advantage for amorphous drugs 77, in addition to 
differentiating between GFA classifications of compounds 76. Tm can also dictate the type of manufacturing 
method suitable for a particular SD commercial product due to heat unstable components and risks of 
chemical degradation 45, as well as being related to their glass transition temperature 81. 
 
5.3 Lipophilicity (logP, clogP, logD7.4) 
Lipophilicity remains an important property of drug candidates in development over the last 15-20 years, due 
in part to the lipophilic molecular requirements of new drug targets 19, 82. It is thought to be correlated with 
MW, yet it appears to be changing less overtime than other drug properties 71, 73. A 2016 analysis of 1620 
molecules patented around that time uncovered that around 50% had ligands displaying mean logP ≥4 8. As 
such, Leeson and Springthorpe have even suggested lipophilicty to be the most important drug property, 
where high lipophilicity can result in increased risks of multiple target binding and potential toxicology 71. As 
expected LBF commercialised drugs displayed significantly higher measured logP, clogP and logD7.4 values than 
drugs compounds in the Others dataset. High lipophilicity would be expected to facilitate sufficient drug 
loading capacity in lipid vehicles. It is commonly reported that “grease ball” drug molecules, displaying high 
lipophilicity and relatively low Tm are good candidates for LBFs 83, while the ability to facilitate lymphatic 
uptake by LBFs is optimised for highly lipophilic drugs (logP > 5) 84. Overall, this finding suggests that drugs with 
logP values of approximately 4–5 are good candidates for commercial LBFs due to the mean logP value of 4.7 
observed. Previously, Pouton and Porter have suggested a logP >5 demonstrates suitability for LBF as such 
drug compounds are incorporated into mixed micelles and absorbed efficiently 29. Interestingly, the greatest 
variance in logP values was also found in the LBF group. This could be related to the diverse range of classes of 
LBFs available 59, where differing quantities of lipophilic and hydrophilic excipients in the formulation offers 
greater versatility for incorporating drugs across a range of lipophilicities.  
While SDs did display significantly higher lipophilicity than Others, LBFs and SDs could not be separated in 
terms of this parameter. This reflects analysis by Ditzinger et al. where 66% of SDs in literature displayed LogP 
values of 2-6 7. Previously, a logD cut off of ≤2.7 was suggested as a cut off for SD over LBF formulation class 
suitability in a decision tree tool 85. However, our findings suggest that while lipophilicity provides potential to 
isolate drugs with potential for commercial success via LBF or SD delivery technologies, it does not 
differentiate between them. For example, earlier case studies of Kaletra®, and Norvir® containing highly 
lipophilic drugs (clogP ≥4.7) demonstrate that such drugs can be produced successfully as both LBFs and SDs. 
In these cases, despite high lipophilicity, the SD forms were ultimately more commercially favourable. While 
these provide just two examples, overall, these findings appear to challenge the commonly held belief that 
drugs with high logP values are more suited for LBFs and perhaps, begging the question if our rationale for 
assessing the utility of LBFs may be overly simplistic. As such, while previous research has demonstrated that 
the renowned ability of LBFs to eliminate the food effect does not always stand to scrutiny 50, the current 
results have also demonstrated that LBFs cannot be differentiated from SDs in terms of lipophilicity.  
 
5.4 Aqueous Solubility (logS) 
As expected, among the total dataset of drugs, aqueous solubility (expressed as logS) displayed a significantly 
lower solubility for both LBF and SD drugs versus Others. Interestingly, when excluding high solubility drugs 
from the dataset and reanalysed using only low solubility drugs, significances remained. This indicates that 
even within PWSD classes, LBF and SD technologies offer the opportunity to facilitate commercial 
development as oral drug products. In relating lipophilicity and hydrophilicity, Bergstrom et al. have previously 
suggested that a logP >3 is an indicator of reduced interaction with aqueous solvents 83. In this analysis, our 
mean logP values for commercial LBFs (4.66) and SDs (4.16) both fell above this value. Such results are 
expected as both formulation technologies present a potential delivery solution for drugs encompassing the 
“poor solubility challenge”.  
 
5.5 Percentage Excreted Unchanged in Urine (%U) 
Percentage drug excreted in urine also distinguished drugs suitable for both LBF and SD but not between the 
two delivery techniques. A significantly lower percentage of both LBF and SD drugs were excreted in urine 
compared to the Others dataset. This is not unexpected as drugs excreted in the urine unchanged are typically 
highly water soluble whereas PWSDs require metabolism into metabolites which are likely more polar and 
readily excreted 86. However, a range of factors may influence the predictive ability of this property, including 
need for a bioavailability factor for orally delivered drugs coupled with the fact that that certain drugs or active 
metabolites may be excreted unchanged in bile not urine 49. This property demonstrated that SD and LBF drugs 
are less hydrophilic than Others, similar to our previous result of their higher lipophilicity and lower aqueous 
solubility.  
 
5.6 Rotatable Bond Count (RB) 
SD commercialised products displayed significantly higher mean RB count than both LBF and Others. Once 
again reflecting current trends in drug candidates, as bulk physical properties including MW and RB count have 
increased with time 71. This finding compliments previous observations that compounds exhibiting high 
amorphous stability contain higher numbers of RBs 87. Baird et al. have suggested that higher RB and molecular 
flexibility decreases probability of being incorporated into an ordered crystalline structure 76, and 
demonstrated that both high MW and high RBs are indicative of higher GFA and lower crystallisation tendency 
(i.e. Class III GFA). Elsewhere, the number of RB, providing a measure of molecular flexibility, has been 
suggested by Kuentz et al. to positively influence the amorphous solubility advantage of a drug 77. 
Comparatively higher RBs (e.g. 5-10) were indicative of suitability for a SD formulation approach, and at a 
mechanistic level this most likely reflects the ability of good glass forming drugs to display prolonged 
supersaturation, relative to poor glass former which are at greater risk of precipitation from supersaturated 
solutions. It is also noteworthy that molecular flexibility was not predictive of a LBF approach. Again, at a 
mechanistic level LBF increase drug concentrations via promotion of solubilisation in the intraluminal fluids 
and hence the ability of the inherent amorphous stability of the drug is not a considered to be a factor 
influencing performance.   
 
5.7 Hydrogen Bond Acceptors (HBA) 
HBA count was observed to be a property which distinguished between suitability of SD commercial drugs 
versus both LBFs and others, with a significantly higher mean HBA found for SD drugs (i.e. 6.87). The 
importance of HBA count is reflected in the fact that more than double (24%) of SD drugs had greater than 10 
HBA compared to LBF drugs (10%). Furthermore, when comparing only low solubility drugs the significance of 
the differences between SD and both LBFs and others was strengthened. 
Hydrogen bonding interactions increase both stability and rigidity of the amorphous state by the formation of 
poorly packed aggregates which render crystal formation increasingly difficult 87. Number of HBA has 
previously been significant in modelling both the potential for crystallisation of a drug, based on GFA class 88, 
as well as prediction of the solubility advantage for amorphous drugs 77. In the latter, the number of HBAs was 
the most important descriptor after MW in amorphous solubility advantage prediction. Additionally, hydrogen 
bonding between the API and polymer excipients is an important feature aiding polymers to inhibit drug 
crystallisation and promote amorphous stability. Hydrogen bonding between the two have been observed in 
dispersions displaying lower tendency and highest resistance to crystallisation 89, 90. Second, third and fourth 
generation SDs utilise polymer carriers, either alone or in the presence of other polymers or surfactants 7. In 
this analysis, polymers were found to be the most widely used excipients in commercial SDs for both 
crystalline and amorphous based solid dispersions.  
5.8 Hydrogen Bond Donors (HBD) 
Both HBD and HBA counts are important with regard to Lipinski Rule-of-5 violations, amorphous stability and 
hydrogen bonding interactions between polymeric stabilisers and drugs. However, in this case, HBD was not 
found to be a property distinguishable between LBF, SD or Others in our analysis of the full datasets. However, 
when only low solubility drugs were analysed, a significant difference was observed between SD and Others. 
Previously, amorphous stability was found to be moderately correlated with the number of HBDs upon 
previous examination of a group of PWSDs 87 and positively correlated with MW (r2 = 0.70), previously 
discussed to be influential in Section 5.1. Thus, intensifying the significance of hydrogen bonding capacity in 
distinguishing suitability of drugs for SD commercial success.  
 
5.9 Polar Surface Area (PSA) 
The importance of hydrogen bonding capacity was once again reflected in the fact that PSA distinguished 
suitability of drugs for commercial SDs versus both LBFs and Others.  Significantly higher mean values were 
found for the SD dataset (125.92 Å2), versus LBF (79.68 Å2) and Others (81.48 Å2) which retained significance 
when only low solubility drugs were compared. The spread of values was also the smallest for SD drugs. 
Comparatively, drug development trends indicate the mean PSA of drugs has been increasingly significantly 
through the years 71, 73.  However, it is important to bear in mind that correlation does not imply causation as 
in this case, the increasing prevalence of new drug candidates displaying higher PSA as well as increasing use 
of SD technologies could represent independent trends in both cases or reflect complementarity of both. PSA 
was previously determined a significant descriptor in in silico modelling long term amorphous stability 87 and 
amorphous solubility gain 77. For the later, the authors suggested a comparatively higher value for PSA as a 
property to prompt consideration for SD delivery. They found a range of 60-140 Å2 being indicative of a high 
amorphous solubility gain. In our analysis, the mean PSA for SD commercial drugs was 125.9 Å2, thus, within 
this range.  
 
5.10 Lipinski Rule-of-5 Violations (Ro5) 
We observed a significant association between drug group and prevalence of Ro5 violations. This ‘drug likeness 
filter’ states that, in general, an orally active drug has no more than one violation. Thus, in our analysis we 
used a cut-off of ≤1 (0, 1) or >1 violations (2, 3, 4). After this discrete numerical variable was recoded to a 
categorical variable, we observed both LBF and SD to be significantly different from Others in terms of Ro5 
violations (p ** < 0.01, p *** < 0.001). As such, 30% of SD and 18% of LBF commercial drugs displayed >1 
violation compared to 6% of Others (Supplementary Materials). Without question, the higher Ro5 violations 
observed mirrors the growing number of beyond Ro5 drugs candidates being produced in the search for 
biological selectivity for emerging biological targets 21. It has previously been observed that only approximately 
50% of all drug targets appear accessible by compounds within the Ro5 chemical space 91. As such, extended 
Ro5 (eRo5) and beyond Ro5 (bRo5) compounds refer to those outside this defined chemical space 8. Perhaps 
suggestive that standard drug likeness filters may appear overly conservative as more and more non Ro5 
compliant compounds reach commercial development. As mentioned previously, complementary use of 
formulation likeness filters may provide accurate predictions of formulation success for such troublesome drug 
candidates, as commercial success has been already demonstrated through LBF and SD approaches. 
 
5.11 Dosage Strength (pDose and MDS)  
Although, the LBF dataset demonstrated the lowest mean MDS (118.59mg) and the smallest first quartile value 
among the three groups, no significant differences were observed between the three groups. Conversely, 
upon comparison of only low solubility drugs, both LBF and SD drugs demonstrated significantly lower MDS 
compared to Others (p ** < 0.01, p ** < 0.01). Any lower dosage levels could refer to higher potency where 
smaller doses are required. While conversely PWSD not formulated by enabling formulations may require 
dosage increases to compensate for low bioavailability. A dose of <100mg has previously been suggested as a 
significant factor to consider lipid-based drug delivery systems to dissolve the full dose. To overcome this 
perceived dose limitation LBF suspensions, along with the avocation of chase dosing 92 and use of ionic liquids 
have been suggested 93. Previously, suitable drugs for LBF delivery have been proposed to be low dose drugs 
such as hormones, cytotoxic drugs or prolonged therapy drugs requiring dose titrations 15. Linking to this, two 
of the BDDCS Class I drugs utilising LBFs commercially consisted of Vitamin D and its active metabolite with 
dosage levels in the microgram range (One-Alpha®, Thorens ®, Uvedose ®). Thus, dosage strength may also be 
a factor for previous observation that the second highest proportion of LBF commercial drugs are BDDCS class 
I.   
We also examined dosage strength in terms of pDose. When only low solubility drugs were analysed both LBF 
and SD drugs displayed significantly smaller doses compared to Others (p * < 0.05, p * < 0.05). This was 
somewhat unexpected as a stated advantage of SDs over LBFs is in general, the potential for much higher 
dosage levels, as high API-to-polymer ratios can offer higher drug loadings, echoing the commercial product 
Kaletra® resulting in a decreased pill burden. However, this could be affected by whether a crystalline or 
amorphous-based solid dispersion is produced. Instability of the amorphous form or presence/absence of 
polymers could alter drug loading capacities of amorphous-based solid dispersions.  
 
5.12 Non-Significant Properties 
No trends in pKa were established. However, a previous meta-analysis of 61 articles regarding supersaturating 
drug delivery systems (SDDS) including SD and LBFs between 2010-2015 revealed weakly acidic drugs 
demonstrated the highest improvement in the oral bioavailability-related parameters in comparison to weakly 
basic or neutral drugs 94. However, more extensive research is required as any effect of drug ionisation is 
difficult to analyse.  
5.13 Properties of Drugs Commercialised via Both Bio-Enabling Formulation 
Technologies. 
As stated previously, four drugs have been commercially developed using both LBF and SD technologies. These 
drugs are Fenofibrate, Nimodipine, Ritonavir and Lopinavir. Two drugs displayed >1 Ro5 violation and all four 
were BDDCS Class II. Mean logP, clogP and logD7.4 values for these drugs were high with all drugs displaying 
low aqueous solubility. With regard to Tm, only one drug, Lopinavir, had a Tm above the aforementioned cut off 
for LBFs of 150°C (174.5°C). Thus, it can be suggested that for a drug to act as a commercial candidate for 
success via both technologies it should display an intermediate Tm (e.g. ~150°C) to increase likely solubility in 
the lipid system. Three of the four drugs displayed ≥10 RBs and PSA >120 Å2. Thus, while these properties 
reflect suitability for SDs, they do not, in practice, limit the commercial potential of drugs for success with 
LBFs. MW ranged from 360.83–720.946 g/mol, demonstrating the ability of both technologies to 
accommodate drugs with a wide range of MW. The average number of HBA and HBD were similar to our 
previous values and mean %U was low (1.58%). Overall, it appears clear from the current commercial portfolio 
of products, that PWSD displaying rule-of-5 violations, higher PSAs, a high RB count, mid-range Tm, high HBA 
and HBD count and a low %U, provide potential candidates for commercial development with both LBF and SD 
technologies. While in terms of drug properties which can distinguish between LBF and SD platforms in terms 
of commercial success, this review has demonstrated that drug MW, PSA, RB and HBA count show significant 
















This review examined physiochemical and molecular properties of the current commercial portfolio of drug 
products using LBF and SD formulations. A database of drugs commercially developed as LBFs and SDs was 
reviewed, prevalence of BDDCS class was determined and retrospective trends in drugs properties uncovered. 
It was established that drug properties could distinguish not only LBF and SD bio-enabled commercial drugs 
from Others but also distinguish between commercially successful LBF and SD drugs. The latter involved drug 
properties of MW, RB, HBA and PSA, indicating importance of size, molecular flexibility and hydrogen bonding 
capacity in formulation of SDs. In terms of well-established drug likeness filters, >1 violation of Lipinski’s Ro5 
was seen to be 5 and 3 times more prevalent for SD and LBF drugs, respectively, versus Others. While the Tm of 
55% of commercial LBF drugs exceeded the often reported cut off of 150°C.  A general trend toward increasing 
commercial development of SD formulations in recent years was observed. Encouragingly, many of the 
significant properties established reflect drug discovery trends of recent years, providing a positive outlook for 
potential of bio-enabling formulations to overcome solubility limitations. Furthermore, all drug properties 
included in the “Oral PhysChem Score” system i.e. MW, clogP, RB, Solubility and PSA, indicative of bio-
pharmaceutical performance of a drug, were found to be significant in this analysis 95.  
This is not a definitive nor exhaustive list, drugs which do not fit some properties mentioned may be 
successfully developed in the future and certain properties not deemed significant do have their part to play. 
Moreover, as the numbers of drugs encompassing commercial LBF and SD products continues to grow, 
alterations to these trends may develop as certain properties may emerge or become more influential over 
time. Additionally, it must also be acknowledged that other regulatory considerations such as drug efficacy, 
safety, instability or pharmaceutical commercial interest/priorities will also influence potential for commercial 
success. Utilizing and updating trends going forward can aid the continued growth of both LBF and SD 
commercial products. Retrospective assessments and formulation likeness filters possess capacity to inform 
potential developability, either as a LBF or SD commercial product, based on previously successfully drug 
candidates and success stories over the last few decades. As such, if trends of increasing MW, lipophilic, 
flexible, beyond Ro5, NCEs continue to stem from the discovery pipeline, the need for such bio-enabling 
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Figure 1: Schematic representation of the various classification parameters for drugs using the BCS, BDDCS and DCS 
Classification systems. Red = BCS, Green = BDDCS, Blue = DCS. Drugs are further separated in DCS Class 2, IIa = dissolution 






















Figure 2: Visual representation of modes of action of A) traditional immediate release oral drug products, B) LBF products, 


























Property  Abbreviation Definition 
clogP clogP Logarithm of a molecules partition coefficient between n-octanol and 
using the method of Leo. 
Hydrogen Bond Acceptors HBA Electronegative ion or molecule that must possess a lone electron 
pair in order to form a hydrogen bond. 
Hydrogen Bond Donors HBD Heteroatom with at least one bonded hydrogen. 
logD7.4 logD7.4 Partition coefficient of a drug at pH 7.4. This pH is utilised as this is 
the physiological pH of blood serum. 
logP logP The measured partition coefficient of a molecule between an 
aqueous and lipophilic phases (n-octanol/water). 
logS (mol/L) logS The 10-based logarithm of the solubility of a molecule mol/L. 
Maximum Dosage Strength 
(mg) 
MDS The highest dosage strength licensed for a drug.  
Melting Point (C°) Tm Temperature at which a solid changes state from solid to liquid. 
Molecular Weight (g/mol) MW Molecular Mass of a drug. 
pDose (mol/L) pDose -log10(Maximum Dose Strength) (molar). 
Percentage Excreted 
Unchanged in Urine (%) 
%U The proportion of drug unchanged in the body and excreted in the 
urine.  
pKa (Strongest Acidic) pKa 
(Strongest 
Acidic) 
The pH at which the drug is completely balanced between the 
charged and uncharged form. Strongest acidic refers to the strongest 
acidic group in the molecule. 
Polar Surface Area (Å2) PSA The sum of the fractional contributions to the surface area of all 
nitrogen and oxygen atoms calculated using the method of Clark.  
Rotatable Bonds RB Any single bond, not in a ring, bound to a nonterminal heavy (i.e., 
non-hydrogen) atom. 
Rule of Five Violations Ro5 Number of Lipinski’s Rule-of-Five violations which predicts poor 
absorption or permeation. 
Figure 3: Venn Diagrams illustrating the numbers of LBF (A) and SD (B) commercial products authorised by the FDA and EU 





































































































Figure 7: Visual representation of the statistically significant differences found between LBF, SD and Others. p-values for the 
statistically significant pairwise comparisons are shown. “Total” refers to analysis with all BDDCS Classes. “Low Solubility” 
refers to analysis of only BDDCS Class II/IV. When both “Total” and “Low Solubility” are stated p-value refers to the “Total” 
result. The dark line in the middle of the boxes is the median. The bottom and top of the box indicates the 25th (Q1) and 
75th percentile (Q3). The T-bars are inner fences/whiskers which extend to 1.5 times the box height. The points are outliers 
that do not fall in the inner fences. The asterisks are extreme outliers which have values greater than three times the height 
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1. Results of Statistical Analysis comparing LBF, SD and Others using all BDDCS Classes (Total). 
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Results of the pairwise comparisons completed using BDDCS I-IV classification groups. B = Bootstrap, t = t-test, W = Welch’s test, P = Pearson Chi-Square, F = Fischer’s Exact Test. Bootstrap 95% 
Confidence Interval based upon 5000 stratified bootstrap samples. (L) and (U) refer to lower and upper 95% confidence limits. For non-categorical variables showing normal distribution, when 
Levene’s test was not significant, 95% Confidence intervals and sig. Level for groups comparison were based on ‘equal variance assumed’ calculations i.e independent samples t-test (2 sided). 
When Levene’s test was significant, 95% Confidence intervals and sig. Level for group’s comparison were based on ‘equal variance not-assumed’ calculations i.e Welch’s test. For non-
categorical variables not showing normal distribution the bootstrap method was used (5000 samples). Categorical variables i.e. Ro5, were analysed using Chi-Square tests. If 1 or more cells 

















2. Results of Statistical Analysis comparing LBF, SD and Others using BDDCS Class II/IV (Low Solubility). 
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LBF SD Others 
 
Ro5 No Greater than 1 Count 40 26 714 780 
  
% of Group Total 81.6% 70.3% 93.6% 91.9% 
 
Greater than 1 Count 9 11 49 69 
  
% of Group Total 18.4% 29.7% 6.4% 8.1% 
Total 
 
Count 49 37 763 849 
  
% of Group Total 100.00% 100.00% 100.00% 100.00% 
                                           p-value  
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pDose n 35 30 307 Levene’s Test 0.004 0.000 0.04 
                                           p-value  
Drug Property   Descriptors LBF SD Others Statistical Tests LBF vs SD LBF vs Others  SD vs Others 
 Median 
Mean 























































































pKa (strongest acid) n 
Median 
Mean 




























































































(U) 65.61  
Rotatable Bonds n 
Median 
Mean 


































































Results of the pairwise comparisons completed using BDDCS II/IV classification groups. B = Bootstrap, t = t-test, W = Welch’s test, P = Pearson Chi-Square, F = Fischer’s Exact Test. Bootstrap 
95% Confidence Interval based upon 5000 stratified bootstrap samples. (L) and (U) refer to lower and upper 95% confidence limits. For non-categorical variables showing normal distribution, 
when Levene’s test was not significant, 95% Confidence intervals and sig. Level for groups comparison were based on ‘equal variance assumed’ calculations i.e independent samples t-test (2 
sided). When Levene’s test was significant, 95% Confidence intervals and sig. Level for group’s comparison were based on ‘equal variance not-assumed’ calculations i.e Welch’s test. For non-
categorical variables not showing normal distribution the bootstrap method was used (5000 samples). Categorical variables i.e. Ro5, were analysed using Chi-Square tests. If 1 or more cells 
had an expected count below 5, Fisher’s exact test was employed. A p-value of 0.05 was used as the significance level for all tests. SD refers to Standard Deviation of the Mean. 
 





















   
LBF SD Others 
 
Ro5 No Greater than 1 Count 31 20 279 330 
  
% of Group Total 81.60% 66.70% 90.90% 88.0% 
 
Greater than 1 Count 7 10 28 45 
  
% of Group Total 18.40% 33.30.% 9.10% 12.00% 
Total 
 
Count 38 30 307 375 
  
% of Group Total 100.00% 100.00% 100.00% 100.00% 
3. Tabular representation of SD commercial products. 
Trade Name Drug Dosage Form/Strength Excipients* Method of Manufacturer 
Afeditab CR® Nifedipine Tablet (30mg) Poloxamer/PVP Spray Drying 
Afinitor® Everolimus Tablet (2.5,5, 7.5, 10mg) HPMC Spray Drying 
Astagraf XL® Tacrolimus Capsule (0.5, 1, 5mg) HPMC Wet Granulation  





Certican® Everolimus Tablet (0.25, 0.5, 0.75, 1mg) HPMC Spray Drying 







Copovidone Melt Extrusion 
Crestor® Rosuvastatin 
Calcium 
Tablet (5, 10, 20, 40mg) HPMC Spray Drying 
Cymbalta® Duloxetine Capsule (30, 60mg (+20mg 
FDA)) 
HPMCAS  
Deltyba® Delamanid Tablet (50mg) Hypromellose Phthalate 
(HPMCP) 
 
Envarsus XR® Tacrolimus Tablet (0.75, 1, 4mg) HPMC Melt Granulation 
Epclusa® Sofosbuvir/ 
Velpatasvir 
Tablet (400/100mg) Copovidone Spray Drying 
Eucreas® Vildagliptin/ 
Metformin HCL 
Tablet (50/850mg + 
50/1000mg) 
HPC Hot Melt Extrusion  





Tablet (50/850mg + 
50/1000mg) 
HPC Hot Melt Extrusion 





Tablet (90/400, 45/200mg) Copovidone Spray Drying 
Incivek® Telaprevir Tablet (375mg) HPMCAS Spray Drying 
Incivo® Telaprevir Tablet (375mg) HPMCAS Spray Drying 
Intelence® Etravirine Tablet (25, 100, 200mg) HPMC Spray Drying 
Isoptin SR-E 
240® 
Verapamil Tablet (240mg) HPMC/HPC Spray Drying 
Kaletra® Lopinavir/Ritonavir Tablet (100/25, 200/50mg) PVP Melt Extrusion 
Kalydeco® Ivacaftor Tablet (75, 150mg) HPMCAS Spray Drying  
Mavyret® Glecaprevir/ 
Pibrentasvir 
Tablet (40/100mg) Copovidone (Type K 28) Melt Extrusion 
Modigraf® Tacrolimus Granules for Oral Suspension 
(0.2,1mg) 
HPMC Spray Drying  
Nimotop® Nimodipine Tablet (30mg) PEG Spray Drying/ Fluid Bed 
Nivadil® Nilvadipine Capsule (16mg,8mg) HPMC Spray Drying 
Norvir® Ritonavir Tablet (100mg) PVP VA 64 Melt Extrusion 
Noxafil® Posaconazole Tablet (100mg) HPMCAS Melt Extrusion 
Trade Name Drug Dosage Form/Strength Excipients* Method of Manufacturer 





HPMCAS Spray Drying  
Prograf® Tacrolimus Capsule (0.5, 1, 3, 5mg) HPMC Spray Drying 
Rezulin® Troglitazone Tablet (200, 300, 400mg) PVP Spray Drying 
Samsca® Tolvaptan Tablet (15, 30 + 60mg) HPMC Granulation  
Shui linjia Silibinin Capsule (70mg) Lecithin  
Sporanox® Itraconazole Capsule (100mg) HPMC Fluid Bed Bead Layering 
Stivarga® Regorafenib Tablet (40mg) Povidone K25  
Venclexta® Venetoclax Tablet (10, 50, 100mg) Copovidone Melt Extrusion 






Copovidone Melt Extrusion 
Votubia® Everolimus Tablet (2.5, 5, 10mg) HPMC Spray Drying 




Tablet (50/100mg) TPGS, Copovidone, 
HPMC 
Spray Drying 
Zortress® Everolimus Tablet (0.25, 0.5, 0.75, 1mg) HPMC Spray Drying 
Data obtained from FDA Drug Label (from Drugs @FDA database), European Summary of Pharmaceutical Characteristics (SPC), Health 
Products Regulatory Authority (HPRA) National Drug Authorisation SPC or Therapeutic Goods Administration (TGA) product information. 
*Excipients listed refer only to selected relevant excipients from the total excipients of the drug products which contribute directly to the 



















4. Tabular representation of LBF commercial products. 
Trade Name Drug Dosage Form/Strength Excipients* 
Absorica® Isotretinoin Hard Gelatine Capsule 
(10,20,25,30,35,40mg) 
Sorbitan Monooleate, Soybean Oil and 
Stearoyl Polyoxylglycerides 
Accutane® Isotretinoin Soft Gelatine Capsule (10,20,40mg) Beeswax, Hydrogenated Soybean Oil 
Flakes, Hydrogenated Vegetable Oil, 
Soybean Oil 
Advil Cold and Sinus® Ibuprofen Liquid Gel Capsule (200mg/30mg) Fractionated Coconut Oil, Poly Ethylene 
Glycol 
Agenerase® Amprenavir Soft Gelatine Capsule (50, 150mg) Polyethylene Glycol 1000 Succinate (TPGS), 
Polyethylene Glycol 400 (PEG 400), 
Propylene Glycol  
Aloxi® Palonosetron Soft Gelatine Capsule (0.5mg)  Mono- and di-glycerides of Capryl/Capric 
acid, Glycerin, Polyglyceryl Oleate, Water, 
and Butylated Hydroxyanisole 
Amitiza® Lubiprostone Soft Gelatine Capsule (8, 24mcg) Medium-Chain Triglycerides 
Aptivus® Tipranivir Soft Gelatine Capsule (250mg) Macrogolglycerol Ricinoleate, Ethanol, 
Mono/diglycerides of Caprylic/Capric acid, 
Propylene Glycol. 
Aptivus® Tipranivir Oral Solution (100mg/mL) Macrogol, Polyethylene Glycol, Propylene 
Glycol, Mono/Diglycerides of 
Caprylic/Capric Acid, Polyoxyl 35 Caster Oil, 
Vitamin E Polyethylene Glycol Succinate 
(TPGS). 
Avodart® Dutasteride Soft Gelatine Capsule (0.5mg) Mono- and Diglycerides of Caprylic/Capric 
acid 
Cipro®  Ciprofloxacin Oral Suspension (250mg/mL, 
500mg/5mL) 
Medium Chain Triglycerides 
Claravis® Isotretinoin Liquid Filled Hard Shell Capsule 
(10,20,30,40mg) 
Hydrogenated Vegetable Oil, Polysorbate 
80, Soybean Oil. 
Clarityn®  Loratadine Soft Gelatine Capsule (10mg) Caprylic/Capric Glycerides, Glycerin, 
Polysorbate 80. 
Convulex® Valproic Acid Soft Gelatine Capsule (150, 300, 
500mg) 
Macrogol 6000, Glycerol Monostearate 44-
55 Type II 
Depakene® Valproic Acid Soft Gelatine Capsule (250mg) Corn Oil 
Detrol La®  Tolterodine Tartrate Extended Release Gelatine Capsule 
(2, 4mg) 
Medium Chain Triacylglycerides, Oleic Acid, 
Gelatin. 
Drisdol® Ergocalciferol Liquid Filled Hard Shell Capsule 
(1.25mg) 
Glycerin, Soybean Oil, Edible Vegetable Oil.  
Epadel®(1) Ethyl 
Eicosapentaenoate 
Soft Gelatine Capsule (500mg) Alpha Tocopherol  
Fenogal® Fenofibrate Hard Gelatine Capsule (200mg) Lauryl Macroglycerides, Macrogol 20,000 
Fortovase® Saquinavir Soft Gelatine Capsule (200mg) Medium Chain Mono- and Diglycerides. 
Gengraf® Cyclosporin Hard Gelatine Capsule (25, 100mg) 
(50mg discontinued) 
Polyethylene Glycol, Polyoxyl 35 Castor Oil, 
Polysorbate 80, Propylene Glycol, Ethanol. 
Trade Name Drug Dosage Form/Strength Excipients* 
Gengraf® Cyclosporin Oral Solution (100mg/mL) Polyoxyl 40, Hydrogenated Castor Oil, 
Polysorbate 80, Propylene Glycol 
Glakay® Menatetrenone Soft Gelatine Capsule (15mg) Carnauba Wax, Hydrogenated Oil, Glyceryl 
Monooleate, PG Esters of Fa, Glycerin. 
Hectorol® Doxercalciferol  Soft Gelatine Capsule (0.5, 1, 2.5mcg) Ethanol, Fractionated Triglyceride of 
Coconut Oil 
Heminevrin® Clomethiazole Soft Gelatine Capsule (192mg) Medium Chain Triglycerides, Glycerol 
Hycamtin® Topotecan Liquid Filled Hard Shell Capsule (0.25, 
1mg) 
Hydrogenated Vegetable Oil, Glyceryl 
monostearate 
Infree® Indomethacin Capsule (100, 200mg) Cremophor RH 60 
Juvela N® Tocopherol 
Nicotinate 
Soft Gelatine Capsule (200mg) Carnauba Wax, Medium Chain 
Triglycerides, Glycol Esters of Fatty Acids, 
Glycerin. 
Kaletra® Lopinavir/ Ritonavir Soft Gelatine Capsule 
(133.3mg/33.3mg) 
Glycerin, Oleic Acid, Polyoxyl 35 Castor Oil, 
Propylene Glycol. 
Kaletra® Lopinavir/ Ritonavir Oral Solution (80+20mg/mL) Ethanol, Glycerin, Polyoxyl 40 
Hydrogenated Castor Oil, Propylene Glycol. 
Ketas® Ibudilast  Sustained Release Granules (10mg) Hydrogenated Castor Oil, Macrogol 6000, 
Cremophor RH 60. 
Lamprene® Clofazimine Soft Gelatine Capsule (50, 100mg) Beeswax, Glycerin, Lecithin, Plant Oils, 
Propylene Glycol. 
Lipofen® Fenofibrate Hard Shell Capsule (50, 150mg) 
(100mg discontinued) 
Gelucire 44/14, Polyethylene Glycol 20,000, 
Polyethylene Glycol 8000, Propylene Glycol 
Lovaza® Omega-3 Acid Ethyl 
Esters 
Soft Gelatine Capsule (900mg/gram)  Soybean Oil. 
Marinol® Dronabinol Soft Gelatine Capsule (2.5, 5, 10mg) Sesame Oil. 
MXL® Morphine Prolonged Release Capsule (30, 60, 
90, 120,150,200mg) 
Hydrogenated Vegetable Oil BP, Macrogol 
6000 Ph Eur 
Navelbine® Vinorelbine Soft Gelatine Capsule (20, 30, 80mg) Anhydrous Ethanol, Glycerol Macrogol 400 
Neoral® Ciclosporin Soft Gelatine Capsule (25, 50, 100mg) Alpha-tocopherol, Ethanol, Propylene 
Glycol, Glycerol, Corn oil-mono-di-
triglycerides, Macrogolglycerol 
hydroxystearate / Polyoxyl 40 
hydrogenated castor oil. 
Neoral® Ciclosporin Oral Solution (100 mg/mL) Alpha–tocopherol, Ethanol, Propylene 
Glycol, Corn oil-mono-di-triglycerides, 
Macrogolgylcerol Hydroxystearate / 
Polyoxy 40 Hydrogenated Castor Oil. 
Nimotop® Nimodipine Soft Gelatine Capsule (30mg) Glycerin, Peppermint oil, Polyethylene 
Glycol 400 
Norvir® Ritonavir Oral Solution (80 mg/mL) Polyoxyl 35 Castor oil, Propylene Glycol, 
Ethanol.  
Norvir® Ritonavir Soft Gelatine Capsule (100 mg) Ethanol, Oleic Acid, Polyoxyl 35 Castor Oil. 
Ofev® Nintedanib Soft gelatine capsule (100mg, 150mg) Triglycerides (Medium-Chain), Hard Fat 
Lecithin (soya)  
Trade Name Drug Dosage Form/Strength Excipients* 
One-Alpha® Alfacalcidol  Soft Gelatine Capsule (1mcg) Sesame Oil (refined) 
Panimun Bioral® Cyclosporin Soft Gelatine Capsule (25, 50, 100mg) Ethanol, Propylene Glycol, Corn Oil 
Mono/Di/Tri-Glycerides, Macrogolglycerol 
hydroxystearate / Polyoxyl 40 
Hydrogenated Caster Oil, Ethanol.  
Pentasa® Mesalazine Extended Release Capsule (250, 
500mg) 
Acetylated Monoglyceride, Castor Oil 
Prometrium® Progesterone Soft Gelatine Capsule (100, 
200,300mg) 
Peanut Oil, Glycerin, Lecithin. 
Rapamune® Sirolimus Oral Solution (1mg/mL) Polysorbate 80 (E433), Phosal 50 PG 
(Phosphatidylcholine, Propylene Glycol, 
Mono-and Diglycerides, Ethanol, Soya Fatty 
Acids and Ascorbyl Palmitate). 
Rayaldee® Calcifediol Extended Release Capsule (0.03mg) Mixture of Lipophilic Emusifier with a HLB 
<7 and an absorption enhancer, oily vehicle 
- mineral oil, liquid paraffins or squalene. 
Restandol Testocaps® Testosterone Soft Gelatine Capsule (40mg) Castor Oil and Propylene Glycol 
Monolaurate (E477) 
Roaccutane® Isotretinoin Soft Gelatine Capsule (10, 20mg) Beeswax, Soya-Bean Oil (refined), Soya-
Bean Oil (hydrogenated). 
Soya-bean Oil (Partially Hydrogenated) 
Rocaltrol® Calcitriol Soft Gelatine Capsule (0.25, 0.5mcg) Fractionated Triglycerides of Coconut Oil  
Sandimmune® Ciclosporin Oral Solution (100 mg/mL) Alcohol  dissolved in Olive Oil, Ph. 
Helv./Labrafil M 1944 CS (Polyoxyethylated 
Oleic Glycerides) Vehicle  
Sandimmune® Ciclosporin Soft Gelatine Capsule (25, 50 and 
100mg) 
Corn Oil, Linoleoyl Macrogolglycerides, 
Glycerol, Ethanol. 
Selbex® Teprenone Hard Gelatine Capsule (50mg) Alpha-tocopherol, Macrogol 6000 
Solufen® Ibuprofen Hard Gelatine Capsule (200mg) Gelucire 44/14  
Sustiva® Efavirenz Oral Solution (30mg/mL) Medium Chain Triglycerides 
Targretin® Bexarotene Soft Gelatine Capsule (75mg) Polysorbate 20, PEG400 
Thorens® Cholecalcifer-ol  Oral Drops Solution (10000IU/mL, 
25000IU/2.5mL) 
Refined Olive Oil 
Tirosint® Levothyroxine Soft Gelatine Capsule (0.025, 0.05, 
0.075, 0.1, 0.125, 0.15, 0.112, 0.137, 
0.088, 0.174, 0.200, 0.013mg) 
Glycerin  
Uvedose® Cholecalcifer-ol Oral Solution (100,000IU/2mL) Glycolyzed Polyoxyethylenated Glycerides 
Vesanoid® Tretinoin Soft Gelatine Capsule (10mg) Beeswax, Hydrogenated Soybean Oil 
Flakes, Hydrogenated Vegetable Oils and 
Soybean Oil 
Vyndaqel® Tafamidis Soft Gelatine Capsule (20mg) Macrogol 400, Polysorbate 20, Butylated 
hydroxytoluene  
Xtandi® Enzalutamide Soft Gelatine Capsule (40mg) Caprylocaproyl Polyoxylglycerides. 
Zantac® Ranitidine Soft gelatine capsule (150, 300mg) Medium Chain Triglycerides, Gelucire 
33/01 
Trade Name Drug Dosage Form/Strength Excipients* 
Zemplar® Paricalcitol Soft Gelatine Capsule (1, 2mcg) Medium Chain Triglycerides (fractionated 




Soft Gelatine Capsule (25mg) ProSorb (proprietary combination of 
Polyethylene Glycol 400, Glycerin, Sorbitol, 
Povidone, Polysorbate 80, and Hydrochloric 
Acid), Isopropyl Alcohol, and Mineral Oil 
Zmax® Azithromycin  Extended Release Oral Suspension 
(27mg/mL) 
Glyceryl Behenate 
Data obtained from FDA Drug Label (from Drugs @FDA database), European Summary of Pharmaceutical Characteristics (SPC), Health 
Products Regulatory Authority (HPRA) National Drug Authorisation SPC or Medicines and Healthcare Products Regulatory Agency (MHRA) 
SPC unless otherwise stated.*Excipients listed refer only to selected relevant excipients from the total excipients of the drug products 
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